Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation.
Yao X, Inselman JW, Ross JS, Izem R, Graham DJ, Martin DB, Thompson AM, Ross Southworth M, Siontis KC, Ngufor CG, Nath KA, Desai NR, Nallamothu BK, Saran R, Shah ND, Noseworthy PA. Yao X, et al. Among authors: izem r. Circ Cardiovasc Qual Outcomes. 2020 Oct;13(10):e006515. doi: 10.1161/CIRCOUTCOMES.120.006515. Epub 2020 Oct 5. Circ Cardiovasc Qual Outcomes. 2020. PMID: 33012172 Free PMC article.
Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.
Graham DJ, Reichman ME, Wernecke M, Hsueh YH, Izem R, Southworth MR, Wei Y, Liao J, Goulding MR, Mott K, Chillarige Y, MaCurdy TE, Worrall C, Kelman JA. Graham DJ, et al. Among authors: izem r. JAMA Intern Med. 2016 Nov 1;176(11):1662-1671. doi: 10.1001/jamainternmed.2016.5954. JAMA Intern Med. 2016. PMID: 27695821
Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System.
Chrischilles EA, Gagne JJ, Fireman B, Nelson J, Toh S, Shoaibi A, Reichman ME, Wang S, Nguyen M, Zhang R, Izem R, Goulding MR, Southworth MR, Graham DJ, Fuller C, Katcoff H, Woodworth T, Rogers C, Saliga R, Lin ND, McMahill-Walraven CN, Nair VP, Haynes K, Carnahan RM. Chrischilles EA, et al. Among authors: izem r. Pharmacoepidemiol Drug Saf. 2018 Mar;27(3):263-271. doi: 10.1002/pds.4375. Epub 2018 Jan 10. Pharmacoepidemiol Drug Saf. 2018. PMID: 29318683
Trends in Erythropoiesis-stimulating agent use and blood transfusions for chemotherapy-induced anemia throughout FDA's risk evaluation and mitigation strategy lifecycle.
Vega A, Zhang R, Wong HL, Wernecke M, Alexander M, Feng Y, Lo AC, Lufkin B, Ryan Q, Izem R, MaCurdy TE, Kelman JA, Graham DJ. Vega A, et al. Among authors: izem r. Pharmacoepidemiol Drug Saf. 2021 May;30(5):626-635. doi: 10.1002/pds.5202. Epub 2021 Feb 22. Pharmacoepidemiol Drug Saf. 2021. PMID: 33534188
Sequential surveillance for drug safety in a regulatory environment.
Martin D, Gagne JJ, Gruber S, Izem R, Nelson JC, Nguyen MD, Ouellet-Hellstrom R, Schneeweiss S, Toh S, Walker AM. Martin D, et al. Among authors: izem r. Pharmacoepidemiol Drug Saf. 2018 Jul;27(7):707-712. doi: 10.1002/pds.4407. Epub 2018 Mar 5. Pharmacoepidemiol Drug Saf. 2018. PMID: 29504168 No abstract available.
43 results